Target type: biologicalprocess
Any process that stops, prevents or reduces the frequency, rate or extent of CD4-positive, alpha-beta T cell proliferation. [GOC:obol]
Negative regulation of CD4-positive, alpha-beta T cell proliferation is a complex process that ensures proper immune homeostasis and prevents excessive T cell activation, which could lead to autoimmune diseases. This regulation involves a multifaceted network of signaling pathways, transcription factors, and inhibitory molecules, working in concert to fine-tune T cell responses.
Here's a detailed breakdown of the key mechanisms involved:
1. **Antigen Recognition and Initial Activation:**
- CD4-positive, alpha-beta T cells, also known as helper T cells, are crucial for orchestrating immune responses. They recognize antigens presented by antigen-presenting cells (APCs) through their T cell receptor (TCR).
- Upon antigen recognition, the TCR complex initiates a cascade of signaling events leading to T cell activation.
2. **Signaling Pathways:**
- **TCR signaling:** The TCR complex activates several downstream signaling pathways, including the PI3K/AKT, MAPK, and NF-κB pathways. These pathways control gene expression and cellular processes essential for T cell activation and proliferation.
- **Co-stimulatory signals:** In addition to TCR signaling, co-stimulatory molecules like CD28, ICOS, and OX40 play a crucial role in promoting T cell activation.
3. **Inhibitory Mechanisms:**
- **CTLA-4:** Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) is a crucial inhibitory receptor expressed on activated T cells. It competes with CD28 for binding to CD80/CD86 on APCs, effectively dampening TCR signaling and suppressing T cell activation.
- **PD-1:** Programmed cell death-1 (PD-1) is another inhibitory receptor upregulated on activated T cells. PD-1 interacts with its ligands, PD-L1 and PD-L2, expressed on various cells, including APCs, tumor cells, and even T cells themselves. PD-1 signaling inhibits T cell activation, proliferation, and cytokine production.
- **LAG-3:** Lymphocyte activation gene 3 (LAG-3) is another inhibitory receptor that binds to MHC class II molecules on APCs. LAG-3 engagement suppresses T cell activation and cytokine production, particularly in chronic infections and cancer.
4. **Transcriptional Regulation:**
- **Foxp3:** Forkhead box P3 (Foxp3) is a transcription factor that plays a central role in the development and function of regulatory T cells (Tregs). Tregs are specialized T cells that suppress the activity of other T cells, contributing to immune tolerance.
- **Transcriptional repression:** Several transcription factors, including Blimp-1, Egr2, and Maf, suppress the expression of genes involved in T cell activation and proliferation.
5. **Cytokine Modulation:**
- **IL-10:** Interleukin-10 (IL-10) is an immunosuppressive cytokine that inhibits T cell proliferation and promotes Treg development.
- **TGF-β:** Transforming growth factor-beta (TGF-β) is a pleiotropic cytokine that can either promote or inhibit T cell proliferation depending on the context. It primarily acts as an inhibitory factor, suppressing T cell activation and promoting Treg differentiation.
6. **Apoptosis and Exhaustion:**
- **Apoptosis:** In the absence of appropriate signals or under conditions of sustained activation, T cells can undergo programmed cell death (apoptosis), eliminating potentially harmful cells.
- **T cell exhaustion:** Chronic antigen stimulation can lead to T cell exhaustion, a state characterized by reduced effector function and increased expression of inhibitory receptors like PD-1. Exhausted T cells contribute to immune evasion in chronic infections and cancer.
7. **Immune Homeostasis and Tolerance:**
- The complex interplay of these regulatory mechanisms ensures that immune responses are tightly controlled. By inhibiting excessive T cell activation and proliferation, negative regulation of CD4-positive, alpha-beta T cells is crucial for maintaining immune homeostasis and preventing autoimmune diseases.
- This regulation also contributes to immune tolerance, preventing the immune system from attacking self-tissues and maintaining a balance between immune responses and self-protection.
In summary, negative regulation of CD4-positive, alpha-beta T cell proliferation is a multi-layered process involving signaling pathways, inhibitory receptors, transcription factors, and cytokines. This intricate regulation ensures proper T cell activation, prevents autoimmune diseases, and contributes to immune homeostasis and tolerance.'
"
Protein | Definition | Taxonomy |
---|---|---|
Programmed cell death 1 ligand 1 | A programmed cell death 1 ligand 1 that is encoded in the genome of human. [PRO:WCB, UniProtKB:Q9NZQ7] | Homo sapiens (human) |
Arginase-2, mitochondrial | An arginase-2, mitochondrial that is encoded in the genome of human. [PRO:DNx, UniProtKB:P78540] | Homo sapiens (human) |
Galectin-9 | A galectin-9 that is encoded in the genome of human. [PRO:DNx, UniProtKB:O00182] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
lactose | beta-lactose : The beta-anomer of lactose. lactose : A glycosylglucose disaccharide, found most notably in milk, that consists of D-galactose and D-glucose fragments bonded through a beta-1->4 glycosidic linkage. The glucose fragment can be in either the alpha- or beta-pyranose form, whereas the galactose fragment can only have the beta-pyranose form. Lactose: A disaccharide of GLUCOSE and GALACTOSE in human and cow milk. It is used in pharmacy for tablets, in medicine as a nutrient, and in industry. | lactose | |
sesamin | (+)-sesamin : A lignan that consists of tetrahydro-1H,3H-furo[3,4-c]furan substituted by 1,3-benzodioxole groups at positions 1 and 4 (the 1S,3aR,4S,6aR stereoisomer). Isolated from Cinnamomum camphora, it exhibits cytotoxic activity. | benzodioxoles; furofuran; lignan | antineoplastic agent; neuroprotective agent; plant metabolite |
methyl alpha-d-galactopyranoside | methyl alpha-D-galactoside : An alpha-D-galactoside having a methyl substituent at the anomeric position. methyl-galactopyranoside: structure in first source | alpha-D-galactoside; methyl D-galactoside; monosaccharide derivative | |
methyl beta-galactoside | methyl beta-D-galactoside : A beta-D-galactopyranoside having a methyl substituent at the anomeric position. methyl beta-galactoside: RN given refers to (beta-D)-isomer methyl galactoside : A methyl glycoside in which the H of the OH group on C-1 of galactose is replaced by a methyl group. | beta-D-galactoside; methyl D-galactoside; monosaccharide derivative | |
thiodigalactoside | thiodigalactoside: RN given refers to beta-D-galactopyranoside (D-Gal)-isomer | ||
methyl lactoside | beta-D-Gal-(1->4)-beta-D-Glc-OMe : A methyl glycoside comprising methyl beta-D-glucoside having an beta-D-galactosyl residue at the 4-position. | disaccharide derivative; methyl glycoside | |
n(omega)-hydroxyarginine | N(5)-[(Z)-amino(hydroxyimino)methyl]-L-ornithine : An N(5)-[amino(hydroxyimino)methyl]-L-ornithine in which the double bond has Z-configuration. N(omega)-hydroxyarginine: can cause vasorelaxation of bovine intrapulmonary artery; structure given in first source | amino acid zwitterion; N(5)-[(E)-amino(hydroxyimino)methyl]ornithine; N(5)-[(hydroxyamino)(imino)methyl]ornithine; N(5)-[(Z)-amino(hydroxyimino)methyl]ornithine; N(5)-[amino(hydroxyimino)methyl]-L-ornithine; N(5)-[amino(hydroxyimino)methyl]ornithine; N(omega)-hydroxy-L-arginine | |
pomalidomide | 3-aminophthalimidoglutarimide: structure in first source | aromatic amine; dicarboximide; isoindoles; piperidones | angiogenesis inhibitor; antineoplastic agent; immunomodulator |
n-acetyllactosamine | N-acetyllactosamine : A beta-D-galactopyranosyl-(1->4)-N-acetyl-D-glucosamine having beta-configuration at the reducing end anomeric centre. N-acetyllactosamine: RN given refers to D-isomer | beta-D-Galp-(1->4)-D-GlcpNAc | |
Nomega-hydroxy-nor-l-arginine | L-alpha-amino acid | ||
galactal | galactal: RN given refers to cpd with unspecified isomeric designation; structure | anhydrohexose; glycal | |
apiin | apiin : A beta-D-glucoside having a beta-D-apiosyl residue at the 2-position and a 5,4'-dihydroxyflavon-7-yl moiety at the anomeric position. apiin: structure | beta-D-glucoside; dihydroxyflavone; glycosyloxyflavone | EC 3.2.1.18 (exo-alpha-sialidase) inhibitor; plant metabolite |
fosbretabulin | stilbenoid | ||
(S)-2-amino-6-boronohexanoic acid | (S)-2-amino-6-boronohexanoic acid : L-Norleucine substituted at C-6 with a borono group. | non-proteinogenic L-alpha-amino acid; organoboron compound | |
2-amino-6-boronohexanoic acid |